Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 8/20 | 0.87 |
| ▸ | MGAM | O43451 | 4/20 | 0.87 |
| ▸ | AGL | P35573 | 3/20 | 0.57 |
| ▸ | GBA1 | P04062 | 4/20 | 0.50 |
| ▸ | SI | P14410 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LCT | P09848 | 1/20 | 0.50 |
| ▸ | GBA2 | Q9HCG7 | 7/20 | 0.48 |
| ▸ | UGCG | Q16739 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135276 | 1.00 | GAA (0.87) | GAAMGAMAGLGBA1SI | |
| SCHEMBL9495437 | 1.00 | GAA (0.87) | GAAMGAMAGLGBA1SI | |
| SCHEMBL6135315 | 1.00 | GAA (0.87) | GAAMGAMAGLGBA1SI | |
| SCHEMBL10824953 | 1.00 | GAA (0.87) | GAAMGAMAGLGBA1SI | |
| Hydrochloric Acid SCHEMBL7623702 | 0.98 | GAA (0.83) | GAAMGAMAGLGBA1SI | |
| SCHEMBL23503296 | 0.93 | GAA (1.00) | GAAMGAMAGLGBA1SI | |
| SCHEMBL2434604 | 0.93 | GAA (1.00) | GAAMGAMAGLGBA1SI | |
| SCHEMBL8262434 | 0.93 | GAA (1.00) | GAAMGAMAGLGBA1SI | |
| SCHEMBL19227865 | 0.93 | GAA (1.00) | GAAMGAMAGLGBA1SI | |
| SCHEMBL11159128 | 0.93 | GAA (1.00) | GAAMGAMAGLGBA1SI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960610-B2 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | NOVO NORDICK, A/S (DK) | 2005-11-01 | — | — | US | claimed |
| EP-1558245-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | claimed |
| WO-2004037233-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | claimed |
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | NOVO NORDISK A/S (DK) | 2004-04-29 | — | — | US | claimed |
| US-20040082646-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | RYTVED KLAUS ASGER (DK) | 2004-04-29 | — | — | US | claimed |
| EP-0858335-B1 | 2-ALKYLPYRROLIDINES | NOVO NORDISK AS (DK) | 2003-03-12 | — | — | EP | claimed |
| US-6451836-B1 | Method of inhibiting liver glycogen phosphorylase with 2-alkylpyrrolidines | NOVO NORDISK A/S (DK) | 2002-09-17 | — | — | US | claimed |
| EP-1040827-A2 | Use of 2-alkylpyrrolidines for the treatment of diabetes | NOVO NORDISK A/S (DK) | 2000-10-04 | — | — | EP | claimed |
| JP-3043430-B2 | — | — | 2000-05-22 | — | — | JP | claimed |
| EP-0858335-A1 | 2-ALKYLPYRROLIDINES | NOVO NORDISK A/S (DK) | 1998-08-19 | — | — | EP | claimed |
| WO-1997009040-A1 | 2-ALKYLPYRROLIDINES | NOVO NORDISK A/S (DK) | 1997-03-13 | — | — | WO | claimed |
| EP-0322395-B1 | HETEROCYCLIC COMPOUNDS FOR INHIBITING VIRUS | Monsanto Company (US) | 1993-03-24 | — | — | EP | claimed |
| EP-0322395-A1 | Heterocyclic compounds for inhibiting virus | Monsanto Company (US) | 1989-06-28 | — | — | EP | claimed |
| US-12378584-B2 | Methionine analogue synthesis | ENGENES BIOTECH GMBH (AT) | 2025-08-05 | — | — | US | disclosed |
| EP-4547265-A1 | TREATING AUTOIMMUNE DISEASES WITH INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR LIGAND CONJUGATED TO AN AGENT | Lirum Therapeutics, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| WO-2025056760-A1 | SURGERY TENT HAVING A REPOSITIONABLE STABILISING ELEMENT | SURGITENT GMBH (DE) | 2025-03-20 | — | — | WO | disclosed |
| US-4937357-A | ACYLATED DERIVATIVES OF 1,4-DIDEOXY-1,4-IMINO-L-ARABINOL | G. D. SEARLE & CO. (US) | 1990-06-26 | — | — | US | disclosed |
| EP-0367747-A2 | Dideoxy-L-arabinitol derivatives as antiviral compounds | G.D. Searle & Co. (US) | 1990-05-09 | — | — | EP | disclosed |
| EP-0322395-A1 | Heterocyclic compounds for inhibiting virus | Monsanto Company (US) | 1989-06-28 | — | — | EP | disclosed |
| EP-0322395-A1 | Heterocyclic compounds for inhibiting virus | Monsanto Company (US) | 1989-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | PYGM, GYS1, AGL | GAA 43/4885MGAM 13/4885AGL 3/4885 |
| US-20040082646-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | PYGM, GYS1, AGL | GAA 45/4885MGAM 12/4885AGL 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.